Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

(2020) Brandon Michael Henry et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

(2020) Ruggero Capra et al.   European Journal of Internal Medicine

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Reporting of all cardiac medications and their outcome in COVID - 19

(2020) Ajay Kumar Mishra et al.   JOURNAL OF MEDICAL VIROLOGY

Treatment options for COVID-19: The reality and challenges

(2020) Shio-Shin Jean et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

(2020) Jingyuan Liu et al.   Journal of Translational Medicine

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

(2020) Pavan K. Bhatraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 pandemic and non invasive respiratory management: Every Goliath needs a David. An evidence based evaluation of problems

(2020) J.C. Winck et al.   Pulmonology

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

(2020) Andrey A Ivashchenko et al.   CLINICAL INFECTIOUS DISEASES

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

(2020) Fatemeh Heidary et al.   JOURNAL OF ANTIBIOTICS

Clinical course and characteristics of patients with coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study

(2020) Yanfang Liu et al.   Aging-US

Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?

(2018) Rebecca E. Chandler   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Detoxification mechanisms involved in ivermectin resistance in the cattle tick, Rhipicephalus (Boophilus) microplus

(2018) Valeria Lis Le Gall et al.   Scientific Reports

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug

(2012) E. Mastrangelo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY